agilon health (AGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Tim O'Rourke appointed as Chief Executive Officer, President, and Class III Director, effective May 7, 2026, following an employment agreement signed April 24, 2026.
O'Rourke brings extensive healthcare leadership experience from Help at Home, Centene Corporation, Ascension Complete, and Humana.
Voting matters and shareholder proposals
No changes to the proposals to be acted on at the Annual Meeting; shareholders are not voting on O'Rourke's appointment.
Previously submitted proxies and voting instructions remain valid for the Annual Meeting.
Board of directors and corporate governance
O'Rourke appointed as a Class III Director with a term expiring at the 2027 annual meeting.
No family relationships or related party arrangements involving O'Rourke and current directors or executives.
Latest events from agilon health
- Q2 2026 delivered strong revenue growth and profitability, prompting raised full-year guidance.AGL
Q2 2026 - Cost trends are improving as growth, clinical initiatives, and payer negotiations drive future performance.AGL
2024 Wells Fargo Healthcare Conference - Directors reelected, auditor ratified, and executive pay approved with no shareholder questions.AGL
AGM 2026 - Profitability surged in Q1 2026, prompting raised full-year guidance for key metrics.AGL
Q1 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.AGL
Proxy filing - Proxy covers director elections, auditor ratification, pay-for-performance, and ESG priorities.AGL
Proxy filing - Shareholders approved a reverse stock split and adjournment proposal, both backed by the Board.AGL
EGM 2026 - 2026 guidance targets breakeven EBITDA and $5.5B revenue after cost discipline and transformation.AGL
Q4 2025 - Q3 revenue up 28% to $1.45B, but net loss widened to $118M and guidance was lowered.AGL
Q3 2024